Omeros Corporation (OMER)
Company Description
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders.
The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction.
In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders.
Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Country | United States |
IPO Date | Oct 8, 2009 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 196 |
CEO | Dr. Gregory A. Demopulos M.D. |
Contact Details
Address: 201 Elliott Avenue West Seattle, Washington 98119 United States | |
Phone | 206-676-5000 |
Website | omeros.com |
Stock Details
Ticker Symbol | OMER |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001285819 |
CUSIP Number | 682143102 |
ISIN Number | US6821431029 |
Employer ID | 91-1663741 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Gregory A. Demopulos M.D. | Co-Founder, Chairman, Chief Executive Officer and President |
Michael A. Jacobsen | Chief Accounting Officer, Vice President of Finance and Treasurer |
Peter B. Cancelmo J.D. | Vice President, General Counsel and Corporate Secretary |
Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder |
Dr. George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer and Vice President of Science |
Peter W. Williams | Vice President of Human Resources |
Dr. Catherine A. Melfi Ph.D. | Chief Regulatory Officer and Vice President of Regulatory Affairs and Quality Systems |
Nadia Dac | Vice President and Chief Commercial Officer |
Dr. Andreas Grauer M.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 7, 2024 | 8-K | Current Report |
Jan 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Nov 9, 2023 | 10-Q | Quarterly Report |
Nov 9, 2023 | 8-K | Current Report |
Oct 16, 2023 | 8-K | Current Report |
Sep 20, 2023 | 144 | Filing |
Aug 9, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |